期刊
LEUKEMIA & LYMPHOMA
卷 53, 期 4, 页码 525-536出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2011.618235
关键词
Myelodysplastic syndrome; cytogenetics; deletion 5q; complex karyotype; prognostic marker; molecular marker
资金
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
- Deutsche-Jose-Carreras Leukamie-Stiftung e.V. [DJCLS R 10/22]
- Deutsche Krebshilfe e.V [109003]
- H.W. & J. Hector Stiftung [M 47.1]
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and a high propensity to transform to acute myeloid leukemia (AML). In the pathogenesis of the disease, both gene mutations and cytogenetic changes play an important role. The latter have been integrated into prognostic scoring systems including the IPSS (International Prognostic Scoring System) and WPSS (World Health Organization [WHO] classification-based Prognostic Scoring System). In these systems and in multivariate analyses comparing clinical and genetic data, complex karyotypes are associated with a particularly poor prognosis. del(5q) plays a distinct role by classifying the only genetically defined WHO subtype. Also, due to advancement in technology such as whole genome sequencing, the number of known mutations occurring in MDS is steadily increasing. Important recent discoveries include mutations in EZH2, DNMT3A, ASXL1 and IDH1/2. Like TET2, the most commonly mutated gene in MDS, all are involved in epigenetic regulation. Mutations such as ASXL1, RUNX1, EZH2, ETV6/TEL and TP53 have an adverse impact on patient overall survival. Early evidence suggests that some mutations might influence treatment response, necessitating reassessment of the prognostic effect of genetic alterations in the light of every new treatment. This review discusses clinical and biological effects of the most common cytogenetic and molecular aberrations in patients with MDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据